Adjuvant Comparison and Characterization (HIV)

佐剂比较和表征（HIV）

• 批准号: 10834856
• 负责人: BALI PULENDRAN
• 金额: $ 178.1万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10834856
• 关键词: Adjuvant; Antibody Response; Antigens; Encapsulated; Fingerprint; Gel; Goals; HIV; HIV vaccine; Immune; Immune response; Immunologics; Infection; Learning; Mucous Membrane; Side; Tissues; Vaccines; Work; clinically relevant; lipid nanoparticle; neutralizing antibody; nonhuman primate; programs; vaccine development

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms. A major challenge for HIV vaccine development is learning how to induce robust and durable antibody responses that protect against mucosal infection. A critical step on the path to overcoming this challenge are developing adjuvants that appropriately stimulate robust and durable immune responses. The goal of this project is to assess the impact of 3 different adjuvants on enhancing the magnitude and durability of neutralizing antibody responses against HIV Env.

调整比较和表征（ACC）程序的目的是支持调节器与临床相关疫苗/抗原平台相结合的并排比较，并建立了通​​过不同机制起作用的调节器的全身性和组织特异性免疫学特征（“免疫指纹”）。 HIV疫苗开发的主要挑战是学习如何诱导防止粘膜感染的稳健耐用抗体反应。克服这一挑战的路径的关键步骤是开发适当刺激健壮和耐用免疫调查的调节器。该项目的目的是评估3个不同的调节器对增强对HIV Env的中和抗体反应的幅度和耐用性的影响。